Peter Nash (@drpnash) profile picture

Rheumo, Golfer(pathetic), Caravaggisti, Prof School of Medicine Griffith University, A/Prof Univ. of Qld, Director Rheumatology Research Unit Sunshine Coast,

Sunshine Coast
Joined December 2011
Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)
Schett - relapse rates different imids 14.5% APLAR Seoul 2026 #CART #RheumNow
3
Schett - in remission : 14 normal pregnancies no SLE recurrence , babies normal b cells APLAR Seoul 2026 #CART #RheumNow
2
Schett : in vivo the future if it works, during LD aciclovir, co-trimoxazole, CAR-T expansion amount not associated with toxicity, 3 month no vaccination window, all tissues B cell depletion , naive b cells return APLAR Seoul 2026 #CART #RheumNow
1
Georg Schett : cure prime goal of therapy! remission off all treatment , APLAR Seoul 2026 #CART #RheumNow
2
ExVivo advantages APLAR Seoul 2026 #CART #RheumNow
6
lymphodepletion depends on individual cytokine profile and fludarabine PK effects efficacy APLAR Seoul 2026 #CAR-T #Rheum Now
5
number of naive-like CAR-T infused associates with prolonged survival but highly variable APLAR Seoul 2026 #CAR-T #Rheum Now
6
Prof Cam Turtle,Sydney, ex-vivo CAR-T for oncology - 2-6 wk wait for expansion problematic, no CRS unlikely ICANS, APLAR Seoul 2026 #CAR-T #RheumNow
5
CAR-T cell therapy - hottest topic in autoimmune disease - symposium APLAR Seoul 2026 #CAR-T #RheumNow
7
Kreis L, Petzinna S, Kern S,MTX for Remission Maintenance Following Tocilizumab & GCs Induction in GCA Randomized METEORITICS Trial Arthritis Rheumatol. 2026; 78 (suppl 9). acrabstracts.org/abstract/mt…. Accessed October 3, 2026. is there really a role for MTX in GCA? #GCA #RheumNow
3
108